Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2

Investigators tested the activity of co-targeting of estrogen receptor, HER2, and cyclin-dependent kinases 4/6 therapy with tucatinib, palbociclib, and fulvestrant in HR+/HER2+ human breast tumor cell lines and xenograft models.